Sharekhan's research report on Ipca Laboratories
Quarterly revenues reached Rs. 2,355 crore, marking a 16% y-o-y increase and a 13% rise from the previous quarter. Profit after tax (PAT) came in strong at Rs. 245 crore, up 39% as compared to last year and 23%, sequentially. EBITDA stood at Rs. 441 crore, reflecting a 22% y-o-y growth and a 12% increase sequentially. Margins stood at 19%, improving by 102 bps y-o-y but slightly declining by 2 bps versus the previous quarter. Market share rose to 2.14% from 2.04% in Q2FY25, with six of its brands now featured in the top-300 brand list.
Outlook
Integration of Bayshore’s generics business into Unichem US would boost growth, aided by recovering international revenue and recent US regulatory approvals that expand production. Strategic investments in biologics and CDMO initiatives add further growth potential, with the stock showing upside at current multiples of 40x and 30x for FY26E and FY27E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
